BioSpace News Archive

EdiGene, Inc., announced the first patient enrolled in multicenter Phase I clinical study of its investigational gene-editing hematopoietic stem cell therapy ET-01 for patients with transfusion dependent β-thalassemia at the Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, and activation of the investigational site at Nanfang Hospital of Southern Medical University in Guangzhou, Guangdong Province.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the quarter ended June 30, 2021, and provided an update on clinical and corporate progress.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following investor and scientific conferences in September.

NovaBay® Pharmaceuticals, Inc. announces that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.

ICU Medical, Inc. and Smiths Group plc announced that ICU Medical has committed1 to acquire the Smiths Medical division in a transaction that is superior to the existing proposed sale of Smiths Medical to Trulli Bidco Limited.

Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo is one of the first companies to be awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway.

Cipher Pharmaceuticals Inc. announced today that it has filed, and the Toronto Stock Exchange has accepted, notice of Cipher’s intention to renew its normal course issuer bid for its common shares

Gennao Bio today announced the appointment of Gary Sender to its board of directors.

Angion Biomedica Corp. announced it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine kinase receptor inhibitor in clinical development for the treatment of fibrotic diseases, including those in the kidney and lung, at 10:00am EDT on Monday, September 20th.

Timely diagnosis and treatment of cancer has become increasingly crucial for reducing the prevalence of the disease, and in particular preventing cancer-related deaths.